General MedicationsORALStandard
LEQSELVI
DEURUXOLITINIB PHOSPHATE
Standard Dose
EQ 8MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LEQSELVI is listed in Drugs@FDA under application 217900 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DEURUXOLITINIB PHOSPHATE Form and strength TABLET;ORAL - EQ 8MG BASE Sponsor SUN PHARM INDS INC Submission history Latest submission status date: 2024-07-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview LEQSELVI is listed in Drugs@FDA under application 217900 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DEURUXOLITINIB PHOSPHATE Form and strength TABLET;ORAL - EQ 8MG BASE Sponsor SUN PHARM INDS INC Submission history Latest submission status date: 2024-07-25 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.